{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:07:19Z","timestamp":1789679239416,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Orthopaedic Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jos.2026.08.014","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:56:54Z","timestamp":1789678614000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of prophylactic pegfilgrastim compared with therapeutic filgrastim for preventing febrile neutropenia during chemotherapy for musculoskeletal tumors: A single-center retrospective study"],"prefix":"10.1016","author":[{"given":"Takaaki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Imura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Wakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetatsu","family":"Outani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironari","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jos.2026.08.014_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","article-title":"Epidemiology of febrile neutropenia","volume":"1","author":"Lyman","year":"2003","journal-title":"Support Cancer Ther"},{"issue":"2","key":"10.1016\/j.jos.2026.08.014_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"issue":"9082","key":"10.1016\/j.jos.2026.08.014_bib3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(97)02307-6","article-title":"Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup","volume":"350","author":"Souhami","year":"1997","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jos.2026.08.014_bib4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1200\/JCO.1993.11.7.1276","article-title":"An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas","volume":"11","author":"Antman","year":"1993","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jos.2026.08.014_bib5","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.jos.2026.08.014_bib6","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jos.2026.08.014_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jos.2026.08.014_bib8","series-title":"NCCN clinical practice guidelines in oncology: myeloid growth factors. Version 2.2024","year":"2024"},{"key":"10.1016\/j.jos.2026.08.014_bib9","series-title":"G-CSF appropriate use guidelines, revised edition 2022","year":"2022"},{"issue":"8 Pt 2","key":"10.1016\/j.jos.2026.08.014_bib10","first-page":"3S","article-title":"Pegylation: engineering improved biopharmaceuticals for oncology","volume":"23","author":"Molineux","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jos.2026.08.014_bib11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","article-title":"Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis","volume":"11","author":"Cooper","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jos.2026.08.014_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2407-13-11","article-title":"Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis","volume":"13","author":"Naeim","year":"2013","journal-title":"BMC Cancer"},{"issue":"23","key":"10.1016\/j.jos.2026.08.014_bib13","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.1158\/1078-0432.CCR-09-0761","article-title":"Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas","volume":"15","author":"Fox","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"Suppl 5","key":"10.1016\/j.jos.2026.08.014_bib14","article-title":"Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy","volume":"30","author":"Tarantino","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jos.2026.08.014_bib15","first-page":"1115","article-title":"The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study","volume":"33","author":"Shibata","year":"2025","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.jos.2026.08.014_bib16","first-page":"529","article-title":"Persistent damage and functional compromise of bone marrow after cancer therapy: potential mechanisms and implications","volume":"6","author":"Zhou","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.jos.2026.08.014_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/jpet.117.240309","article-title":"Semimechanistic bone marrow exhaustion pharmacokinetic\/pharmacodynamic model for chemotherapy-induced cumulative neutropenia","volume":"362","author":"Henrich","year":"2017","journal-title":"J Pharmacol Exp Therapeut"}],"container-title":["Journal of Orthopaedic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265826002800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265826002800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:56:57Z","timestamp":1789678617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0949265826002800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"alternative-id":["S0949265826002800"],"URL":"https:\/\/doi.org\/10.1016\/j.jos.2026.08.014","relation":{},"ISSN":["0949-2658"],"issn-type":[{"value":"0949-2658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of prophylactic pegfilgrastim compared with therapeutic filgrastim for preventing febrile neutropenia during chemotherapy for musculoskeletal tumors: A single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of Orthopaedic Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jos.2026.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}